OlympiA
2021
Adjuvant Olaparib for High-Risk gBRCA-Mutant Early Breast Cancer
In 1,836 patients with HER2-negative, high-risk early breast cancer and germline BRCA1/2 mutation, one year of adjuvant olaparib reduced invasive disease-free survival events compared with placebo.
Result
Efficacy: Invasive disease-free survivalHR 0.58
Below 1 favours adjuvant olaparib, above 1 favours placebo.
- Absolute difference
- 8.8 points
The absolute difference is derived from the event rates.
Also reported: 4-yr OS 89.8% vs 86.4% (HR 0.68).
- Subtopic
- BRCA1/2 adjuvant
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Tutt ANJ, et al. N Engl J Med. 2021;384(25):2394-2405.doi 10.1056/NEJMoa2105215
Discussion & critique
First positive PARP-inhibitor trial in (neo)adjuvant breast cancer. Requires upfront germline BRCA testing, including in early-stage disease.